PQRI Workshop:

TiO2 Use in Pharmaceuticals
Global Regulatory and Technical Challenges

June 13-14, 2023

What could be next?: e.g. E172

PQRI Workshop:

TiO2 Use in Pharmaceuticals – Global Regulatory and Technical Challenges

14 June 2023

Thomas Broschard, EMD Serono





Agenda

- Nanomaterials in Food: The ANSES list
- 2. E172 What and Where?
- 3. EFSA Opinion/Requests and Consortium
- 4. Studies and Results
- 5. Summary & Conclusion



Ban of E171: End or Beginning?

"Substances that occur in human food and for which the presence of manufactured nanomaterials has been proven (characterization using EM in data and literature)"



EU No.	Chemical name	
E 170	Calcium carbonate	
E 171	Titanium dioxide	
E 172 i, ii, iii	Iron oxide	
E 341	Calcium monohydrogen phosphate	
E 551	Silicon dioxide	
E 552	Calcium silicate	
	organic compounds and composites (nanoemulsions, liposomes, micelles, nanocapsules, nanoparticles of lipids)	


Ban of E171: End or Beginning?


"substances present in human food and for which the presence of manufactured nanomaterials is suspected and not confirmed after review of the literature and data"




EU No.	Chemical name	
E 173	Aluminum	
E 341 Calcium phosphate		
E 343	Magnesium phosphate	
E 421	Mannitol	
E 504	Magnesium carbonate	
E 554	Sodium aluminosilicate	
	and many others (30 compounds)	
	https://www.anses.fr/fr/system/files/ERCA2016SA0226Ra.pdf	

E172 What?...









F172

EFSA Opinion 2015



EFSA Journal 2015;13(12):4317

SCIENTIFIC OPINION

Scientific Opinion on the re-evaluation of iron oxides and hydroxides (E 172) as food additives

EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS)2,3

European Food Safety Authority (EFSA), Parma, Italy

ABSTRACT

The Panel on Food Additives and Nutrient Sources added to Food provides a scientific opinion re-evaluating the safety of iron oxides and hydroxides used as food additives (E 172): yellow iron oxide (FeO(OH)-H2O), red iron oxide (Fe₂O₁₎ and black iron oxide (FeO-Fe₂O₁₎. Brown Iron Oxide has been included in this assessment for completeness, due to its importance as a commercial blend. The Panel considered that the particle size and particle size distribution should be included in the specifications. In 1980, an ADI of 0-0.5 mg/kg bw/day was established by JECFA. Absorption of iron from iron oxides is low. The acute oral toxicity of iron oxides is greater than 10 g iron oxide/kg bw. From a subacute and a subchronic toxicity study, the Panel identified a NOAEL for red iron oxide of 1 000 mg/kg bw/day, the highest dose tested. Red (Fe₂O₃) and black (FeO·Fe₂O₃) iron oxide, both in nano- and micro-form, were positive in in vitro genotoxicity assays in mammalian cells. Due to the limitations of the database, and considering the impossibility to read-across between iron oxides with different redox state, the Panel considered that the genotoxicity of iron oxides cannot be evaluated based on the available data. Concerning carcinogenicity and reproductive and developmental toxicity, no signs of toxicity were observed in unpublished studies which were not available and could not be evaluated by the Panel. The Panel concluded that an adequate assessment of the safety of E 172 could not be carried out because a sufficient biological and toxicological database was not available. Refined exposure estimates show that exposure to E 172 ranged from 0.03 mg/kg bw/day for infants to 3.7 mg/kg bw/day for toddlers at the mean and from 0.1 mg/kg bw/day for infants to 9.5 mg/kg bw/day for toddlers at the 95th percentile for the non-brand-loyal

KEY WORD

red iron oxide, black iron oxide, yellow iron oxide-hydroxide, E 172, CI 77492, CI 77491, CI 77499

Suggested citation: ANS Panel (EFSA Panel on Food Additives and Nutrient Sources added to Food), 2015. Scientific Opinion on the re-evaluation of iron oxides and hydroxides (E 172) as food additives. EFSA Journal 2015;13(12):4317, 57 pp. doi:10.2903/j.efsa.2015.4317

Available online: www.efsa.europa.eu/efsajournal

© European Food Safety Authority, 201

The Panel recommended that the minimum, Tier 1 testing according to the EFSA guidance (2012), should be conducted for the material as marketed as the food additive (E 172):



In vivo genotoxicity at the site of contact (gastrointestinal tract) and subchronic toxicity



complete set of genotoxicity studies and subchronic toxicity




absorption, distribution, metabolism and excretion (ADME), in vivo genotoxicity and subchronic toxicity



On request from the European Commission, Question No EFSA-Q-2011-00347, adopted on 17 November 2015.
Panel members: Fernando Aguilar, Riccardo Crebelli, Alessandro Di Domenico, Birgit Dusemund, Maria Jose Frutos, Pierre Galtier, David Gott, Ursula Gundert-Remy, Claude Lambré, Jean-Charles Leblanc, Oliver Lindtner, Peter Moldeus, Alicja Mortensen, Pasquale Mosesso, Agneta Oskarsson, Dominique Parent-Massin, Ivan Stankovic, Ine Waalken

Berendsen, Rudolf Antonius Woutersen, Matthew Wright and Younes Maged. Correspondence: fip@efsa.europa.eu
Acknowledgements: The Panel wishes to thank the members of the former Working Group 'A' Food Additives and Nutrient Sources (2011-2014) and the members of the Standing Working Group on the re-evaluation of food colours: Fernando Aguilar, Riccardo Crebelli, Alessandro Di Domenico, Maria Jose Frutos, Pierre Galtier, David Gott, Claude Lambré, Jean-Charles Leblanc, Agneta Oskarsson, Jeanne Stadler, Paul Tobback, Ine Waalkens-Berendsen and Rudolf Antonius Woutersen for the preparatory work on this scientific opinion and EFSA staff members: Ana Maria Rincon, Alexandra Tard and Stavroula Tasiopoulou for the support provided to this scientific opinion. The ANS Panel wishes to acknowledge all European competent institutions, Member State bodies and other organisations that provided data for this



Consortium Members
















































abbvie







PQRI: Update on E172 | 14.06.2023





EFSA Opinion on E172



EFSA Nano Guidance



Vefsa

Tel Conf.
with EFSA
02/2022 Further Studies
performed



2015 2016 2017 2018 2019 2020 2021 2022 2023



E172 Consortium signed by members Data Submission to EU COM 03/2020



The control of the co

EFSA Request for further data 11/2022



Data Submission to EFSA12/2022




Toxicological Studies Performed



Red

In vivo Comet Assay (OECD 489) Rat, oral



In vitro



Black

In vivo Comet Assay (OECD 489) Rat, oral

90-day oral toxicity, rat (OECD 408)



Yellow

Ames test (OECD 471)

HPRT (OECD 476), L5178Y cells

In vitro MNT (OECD 487), CHO cells

Cellular Uptake (Leeds)

90-day oral toxicity, rat (OECD 408)

- All studies performed under GLP and according to OECD Guidelines (exception: Cellular uptake)
- Submission in 03/2020




In vivo Comet Assay (OECD 489)



or



- Male rats, 6/group
- Dose levels: 500, 1,000 and 2,000 mg/kg bw/day
- 2 oral admin. (day 1,2)
- Vehicle: 0.5% HPMC
- Stomach and Duodenum
- Red E172: Clearly negative in both organs
- Black E172: Clearly negative in duodenum, Highest dose resulted in increase of tail intensity in stomach of 2/6 animals. However, considered to be an artefact and biologically not relevant



Tan & Bajo (2014) Arch Toxicol



90-day Oral Toxicity Study (OECD 408)



or



- Rats (m/f)
- Dose levels:
 0, 100, 300 and 1,000 mg/kg bw/day
- 10 animals/sex/group
- Vehicle: Diet
- Results:
- No adverse effects up to the highest dose
- No aberrant crypt foci
- NOAEL = 1,000 mg/kg bw/day




Treatment: 13 weeks

Recovery: 4 weeks

Investigations:

- Clinical symptoms
- Functional Observation Battery
- Body weight and body weight gain
- Food/water consumption
- Hematology, clinical chemistry
- Urinalysis
- Gross necropsy
- Organ weights
- Histopathology
- Aberrant Crypt Foci
- Toxicokinetics







In Vitro Genotoxicity with




Test


- **OECD 471** (Ames test) up to 5,000 μg/plate +/- S9
- **OECD 476** (HPRT test) gene mutation L5178Y mouse lymphoma cells up to 100 μg/mL, +/-S9
- **OECD 487** (in vitro MNT test) clastogenicity/aneugenicity CHO cells up to 300 μg/mL, +/-S9







Result





Negative



Negative



In vitro Cellular Uptake



Swansea University & University of Leeds

L5178Y cells (HPRT):

No cellular uptake,

test material attached to cell surface




Figure 5 — Example electron micrographs of L5178Y cells treated with 100.1 µg/ml IRON OXIDE SICOVIT® YELLOW 10 E172. (A) - TEM image of L5178Y cells showing the presence of the test material at the cell surface (highlighted by the red arrows and the red box). No evidence of cellular uptake of test material is visible. The region highlight in the red box is displayed in (B) at higher magnification, the red arrow showing the location and morphology of the test material.

CHO cells (in vitro MNT): Clear cellular uptake





Figure 11 – Example electron micrographs of CHO cells treated with 75 μ g/ml IRON OXIDE SICOVIT® YELLOW 10 E172. (A) - TEM image showing localisation of the test material in CHO cells highlighted by the red arrows and the red box). The region highlight in the red box is displayed in (B) at higher magnification, the red arrows showing membrane bound test material (i) and test material free in the cytoplasm (ii).





EFSA Request for Clarification (11/2022)



Request for clarifications on the data submitted for the assessment on iron oxides and iron hydroxides (E 172):

- Physicochemical Characterisation
 - Composition, Coating, Particle Size Analysis
- Safety evaluation strategy and corresponding testing strategy
 - Reference to EFSA SC Guidance on particle-TR
 - ...you are invited to provide scientific evidence, supported by data, confirming that the safety studies provided for the assessment of E 172 are adequate for addressing the safety of the fraction of small particles, including nanoparticles, according to the principles indicated in Section 4 of the EFSA SC Guidance on particle-TR. P
 - ...demonstrate that the test material(s) used in the safety studies included the fraction of small particles
 - demonstrate the adequacy of the study design of the existing toxicity and genotoxicity studies for covering the hazard assessment of the fraction of small particles,



Vehicles and Preparations (in vivo)


Study	Test Item	Vehicle	Dose/Conc.	Comment
90-day, oral rat (OECD 408)		Diet (ssniff®-R/M-H V1530, ssniff® Spezialdiäten GmbH, 59494 Soest, Germany)	100, 300, 1,000 mg/kg bw/day (1, 5 and 20 g/kg diet)	Premix, mixer (Röhnradmischer)
In vivo Comet Assay (OECD 489)		Aqueous Hydroxypropyl methylcellulose 0.5%	500, 1,000, 2,000 mg/kg bw/day	The test article was weighed into a formulation bottle.
			(50, 100, 200 mg/mL)	Vehicle was added to achieve the final volume. Formulations were then vortex mixed to stir



Vehicles and Preparations (in vitro)

Study	Test Item	Vehicle	Dose/Conc.	Comment
HPRT (OECD 476) L5178Y Mouse lymphoma cells		RPMI 1640 with additives and 5% horse serum	0.2-100 μg/mL	Vortex, ultrasonication, warming
In vitro MNT (OECD 487)		McCoy`s 5A Medium +10% FCS	<300 µg/mL	Mixing







Particle Characterization




E172 Yellow in rat diet (0.5%)





E172 Yellow in water (1 mg/mL)



- Preparation of test item/diet mixtures comparable to in vivo/in vitro studies
- Analysis by SEM
- Nanofraction in tox studies comparable to or exceeding real samples

% Nano fraction

Rat diet	Gentox in vitro	Capsule	Hard candy shell
51-66.7%	30.2%	1.4 - 3.7%	42.5%



Particle Characterization





- Preparation of test item/diet mixtures comparable to in vivo studies
- Analysis by SEM
- % Nano fraction exceeds real samples

E172 Black in 0.5% HPMC (5 mg/mL)



E172 Black in rat diet (2.3 %)





% Nano fraction


Rat diet	0.5% HPMC	Capsule	Hard candy shell
8-11%	28%	0-2.1%	0%



Particle Characterization



E172 Red in 0.5% HPMC (0.5 %)




- Preparation of test item in Methocel comparable to in vivo studies
- Analysis by SEM
- % nanofraction comparable to real sample

% Nano fraction

0.5% HPMC	Capsule
6.3%	4.1-6.5%





Summary & Conclusion

- In 2015, Efsa has identified data gaps for three different E172 qualities; red, yellow and black
- An Industry Consortium has been formed which performed all studies requested by EFSA
- Based on the studies performed (and literature data) no adverse effect/no hazard has been identified for red, black or yellow E172
- Additional analytical investigations showed that the % nano fraction in the different test item formulation are comparable to real samples
- Based on the available data, red, yellow and black E172 are considered to be safe for food and pharmaceuticals
- EFSA opinion is expected to be published in 2024





Acknowledgments

VENATOR

EBRC ...

- Martin Zilse
- Mark Booth
- Markus Rohe
- David Lockley

- Andreas Westphal
- Arne Burzlaff
- Roger Battersby



- Ursula Schliessner
- E172 Consortium



Kevin Hughes



Bram Baert

...and you for your attention

